Evotec (NASDAQ:EVO) Shares Gap Down – Should You Sell?

by · The Cerbat Gem

Evotec AG (NASDAQ:EVO – Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $3.01, but opened at $2.90. Evotec shares last traded at $2.8950, with a volume of 31,269 shares traded.

Analyst Ratings Changes

EVO has been the subject of a number of research reports. Royal Bank Of Canada restated an “outperform” rating on shares of Evotec in a report on Wednesday, September 3rd. HC Wainwright dropped their price objective on Evotec from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, August 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research note on Monday, November 24th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $7.00.

View Our Latest Stock Report on Evotec

Evotec Stock Performance

The company has a 50-day simple moving average of $3.56 and a 200-day simple moving average of $3.78. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.03 and a current ratio of 2.12.

Institutional Trading of Evotec

Several large investors have recently modified their holdings of the business. Valeo Financial Advisors LLC purchased a new stake in Evotec in the 2nd quarter valued at approximately $43,000. BNP Paribas Financial Markets lifted its position in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after acquiring an additional 4,600 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after acquiring an additional 9,289 shares in the last quarter. UMB Bank n.a. acquired a new stake in shares of Evotec during the second quarter valued at $56,000. Finally, Thrivent Financial for Lutherans purchased a new stake in Evotec during the 3rd quarter worth about $53,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.

Read More